MedPath

The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population

Not Applicable
Conditions
Chronic Kidney Insufficiency
Chronic Kidney Diseases
Registration Number
NCT02034149
Lead Sponsor
China Medical University Hospital
Brief Summary

This study is being implemented for 3 aims. The first has been to conduct a systematic literatures review on CKD intervention models and their effectiveness. Findings have been adopted in our intervention program. The second purpose is to establish a practical management model or an intervention model for CKD patients and high risk population with the 18-month of follow-up.In the third year, we will use social perspective point to evaluate the costs and the benefits of intervention.

Detailed Description

The object of the study is by screening for adults (20 years) with chronic kidney disease (CKD stage 1-3a) and high-risk groups. They were randomly assigned into experimental groups (self management and peer-assisted management) and control group (general management). All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.

We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. Information on behavior changes, including smoking, chewing betel nut, medication, exercise and diet, was also collected and assessed. Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc. The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.

In the third year, we will use social perspective point to evaluate the costs and benefits of intervention. We suppose that a 100,000 people to screen out cases of chronic kidney disease (CKD stage 1-3a) and high-risk groups, and we will compare the cost-effectiveness analysis between the experimental group with accept the intervention for 12 months to the control groups without receiving extra intervention.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
411
Inclusion Criteria
  • Age greater than 20 with chronic kidney disease (CKD) stage 1-3a patients and high-risk groups.
Exclusion Criteria
  • Inability to communicate in Chinese.
  • Lack of capacity to write in Chinese.
  • Ongoing treatment in dialysis.
  • Suffering from major diseases.
  • Treatment in cancer or suffering from cancer less than two years.
  • Have received organ transplants or bone marrow transplantation.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Renal function at 18 monthsthe baseline, 3rd, 6th, 12th and 18th months.
Secondary Outcome Measures
NameTimeMethod
Achievement of self management in drug compliance,exercise habit,balance diet at 18 monthsthe baseline, 3rd, 6th, 12th and 18th months.

Trial Locations

Locations (1)

China Medical University Hospital

🇨🇳

Taichung, Taiwan

China Medical University Hospital
🇨🇳Taichung, Taiwan
Chia-Ing Li, doctor
Contact
886-4-22052121
a6446@mail.cmuh.org.tw
Chiu-Ching Huang, PhD
Principal Investigator
Tsai-Chung Li, PhD.
Sub Investigator
Cheng-Chieh Lin, PhD
Sub Investigator
Fung-Chang Sung, PhD
Sub Investigator
Chiu-Shong Liu, doctor
Sub Investigator
Wen-Yuan Lin, PhD
Sub Investigator
Li-Chi Huang, PhD
Sub Investigator
Ya-Fei Yang, doctor
Sub Investigator
Chia-Ing Li, PhD
Sub Investigator
Wen-Chen Tsai, PhD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.